Interview with Ronald Christie, VP Interntaional Operations – General…
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
Address: East Third Ring Road, Chaoyang District, Beijing No. 1 World Financial Center, East Building 18 Zip Code: 100020
Tel: +86 (010) 59615858
Web: http://www.novonordisk.com.cn/documents/home_page/document/index.asp
Novo Nordisk’s products were introduced to the Chinese market as early as the 1960s. In 1994 Novo Nordisk decided to invest in China by setting up Novo Nordisk (Tianjin) Biotechnology Co., Ltd., which was later renamed Novo Nordisk (China) Pharmaceuticals Co., Ltd.
Headquartered in Beijing, Novo Nordisk now employs more than 1,700 employees and has:
• regional offices in Shanghai, Guangzhou, Wuhan, Shenyang, Jinan and Hong Kong,
• production facilities in Tianjin
• a R&D center in Beijing.
Step by step, Novo Nordisk has become the leader in diabetes in China, with a complete organization covering R&D, production, sales and distribution networks.
While providing all major diabetes treatment products and comprehensive diabetes care to people with diabetes in China, Novo Nordisk is also committed to China’s environment and society and has launched social programs such as for example the NovoCare Bus, the NovoCare Club and the “NovoCare Sunshine Program” in Xinjiang, which is an insulin donation program in an earthquake-ravaged area.
R & D, diabetes treatment products, haemostasis management, hormone replacement therapy
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Kite Pharma’s US$1.64B in vivo CAR-T deal with Pregene, Xuanzhu Biopharma’s HKEX debut with a 172% grey market premium,…
This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights CF PharmTech’s HKEX listing with a 227% grey market premium, Eccogene’s HKEX IPO filing at a US$500M…
In just four years, Shanghai-based Argo Biopharma has gone from a start-up to one of China’s most internationally recognised RNA innovators and has signed two major licensing deals with Novartis…
This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights Sichuan Biokin and Binhui Biopharma’s HKEX IPO filings, Betta Pharma’s third IPO attempt, Sirius Therapeutics–B’s HK$1.8B IPO,…
This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights GenFleet Therapeutics’ HKEX IPO, Sciwind’s IPO filing for enoglutide, Biocytogen’s STAR Market approval, Hengrui’s HER2 ADC licensing…
This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights Atom Bioscience’s HKEX IPO, Ark Biosciences’ pipeline funding, Mabwell’s USD 1 billion siRNA deal, HiDiamond Bio’s Pre-Series…
3D Medicines has charted a deliberate path from domestic clinical execution to global oncology innovation. Since its IPO, the company has sharpened its focus on differentiated assets like Envafolimab, while…
This week’s China biopharma roundup from PharmaBoardroom content partner Selesta covers Legend Biotech’s planned secondary listing, Betta’s Hong Kong IPO move, iRegene’s USD 40mn raise after FDA Fast Track for…
This week’s China biopharma roundup from PharmaBoardroom content partner Selesta covers Novartis’ USD 5.4bn expansion with Argo in cardiovascular siRNA, Hengrui’s USD 1.1bn out-licensing of its cardiac myosin inhibitor, Novatim’s…
This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers Gilead’s USD 350mn bet on in vivo CAR-T, GenFleet and Bao Pharma advancing Hong Kong IPOs, Fosun’s…
Chinese biopharma innovators are making real progress toward global expansion. However, as Vera Zhang of Bristol-Myers Squibb (China) Investment Co., Ltd. writes in DIA’s Global Forum magazine, moving beyond exporting…
Jiangsu Hengrui Pharmaceuticals is no longer just a local biopharma heavyweight. With a record-breaking and 450x oversubscribed IPO raising USD 1.27 billion, a flurry of global licensing deals with the…
See our Cookie Privacy Policy Here
